Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Both Endocyte and Merck have much to gain from potential $1bn cancer alliance

This article was originally published in Clinica

Executive Summary

In a $1bn partnership for Endocyte's lead folate-targeting cancer drug candidate and its companion diagnostic, the West Lafayette, Indiana-based biopharmaceutical company gets money to advance more of its early stage programmes and Merck gets access to an oncology therapeutic that may have a better chance of winning regulatory approval than its competitors.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts